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The "antibodyome": or, how to find antibodies?
Abstract
The importance of alloantibodies in acute and chronic allograft rejection has been highlighted over the
past few decades. Besides human leukocyte antigen (HLA) antibodies, representing the most important
group of antibodies in renal transplantation, non-HLA antigens such as MHC class I polypeptide-related
sequence A (MICA) antibodies have also been implicated in renal allograft outcome. However, the
identification of alloantibodies and autoantibodies and their antigens is technically difficult. Recently, Li
and colleagues have performed an integrative genomic analysis of serological responses to non-HLA
antigens in 18 pediatric renal transplant patients to identify new types of antibodies and their tissue
specificity by cross-mapping kidney compartment-specific gene probes to protein targets on a protein
array (1). Several non-HLA targets were detected against kidney compartment-specific antigens with the
highest signal recognition for the renal pelvis. On the one hand, this integrative approach may provide a
powerful and cost-efficient tool to detect autoantibodies involved in autoimmune diseases to investigate
their specificity, relevance and pathogenetic role. On the other hand, the clinical relevance of these
autoantibodies remains to be shown, and it should be explained how mainly intracellular proteins can
provide relevant antigens.
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The importance of alloantibodies in acute and chronic allograft rejection has been 
highlighted over the past decades. Besides HLA-antibodies, representing the 
most important group of antibodies in renal transplantation, non-HLA antigens 
such as MICA antibodies have also been implicated in renal allograft outcome. 
However, the identification of allo- and autoantibodies and their antigens is 
technically difficult.  Now, Li and colleagues performed an integrative genomic 
analysis of serological responses to non-HLA antigens in 18 pediatric renal 
transplant patients in order to identify new types of antibodies and their tissue 
specificity by cross mapping kidney compartment specific gene probes to protein 
targets on a protein array. Several non-HLA targets were detected against kidney 
compartment specific antigens with highest signal recognition for the renal pelvis. 
On the one hand, this integrative approach may provide a powerful and cost-
efficient tool to detect autoantibodies involved in autoimmune diseases to 
investigate their specificity, relevance and pathogenetic role. On the other hand, 
the clinical relevance of these autoantibodies remains to be shown and it should 
be explained how mainly intracellular proteins can provide relevant antigens.  
 
During the last decades, the crucial role of auto- and alloantibodies in kidney 
diseases such as autoimmune glomerulonephritis, Sjögren’s disease or after 
kidney transplant mediating both acute and chronic allograft rejection has been 
highlighted by several studies. In the context of transplant kidney disease, acute 
and chronic allograft rejection have been demonstrated to play a significant role 
in long-term outcome of renal allograft function. Today, detection of C4d in 
peritubular capillaries has been established as the main diagnostic marker of 
antibody-mediated rejection. HLA (major histocompatibility antigen) antibodies 
were shown to be the most important group of antibodies for renal 
transplantation. They can occur as preexisting before transplantation or are 
newly formed as de novo antibodies after transplantation. Donor-specific HLA 
antibodies (DSA) are a specialized subgroup directed against specific donor HLA 
antigens which are strongly correlated with lower graft survival, poor 
transplantation function, and proteinuria. However, antigens other than HLA 
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seem to be responsible for rejection too, as has been recently described by 
Opelz for the Collaborative Transplant Study [1]. In this study, non-HLA 
antibodies have been shown to play a more significant role in clinical 
transplantation than previously thought. In particular, non-HLA immunity was 
associated with chronic graft loss. So far, several types of non-HLA antibodies 
have been identified, such as MICA (MHC class I polypeptide-related sequence 
A) antibodies, Agrin antibodies or agonistic antibodies against the Angiotensin II 
type 1 receptor that may mediate severe vascular rejection and malignant 
hypertension in renal allograft recipients [2, 3]. The identification of non-HLA 
antibodies in kidney transplant rejection or autoimmune disease may therefore 
be very useful as diagnostic and prognostic marker as well as to develop specific 
therapies such as antibody depletion or competition. The major technical 
problem, however, is to identify these antibodies and their antigen targets. 
 
Now, Li and coworkers [4] used a novel approach to perform a screen for novel 
antibodies and compartment-specific non-HLA targets in renal transplant 
recipients. This work was based on previous publications which described high-
density protein microarrays as a potentially powerful and efficient screening 
method to identify serum antibodies against thousands of human proteins in 
autoimmune disease and cancer [5-7]. This method provides a relatively low-cost 
and low-sample volume method to detect antibodies against single and specific 
proteins or peptides. Arrays consist of spotted thousands of recombinant 
(human) proteins or peptides which can be incubated with patients sera to 
measure specific reactivities. In the present study the authors used protein arrays 
to query de novo or augmented post-kidney transplantation antibody responses 
against a selection of HLA and non-HLA targets (in total almost 5600 proteins) in 
18 pediatric transplant recipients. Not surprisingly, the responses between 
patients differed in time course, intensity and proteins recognized. In order to 
address the specificity of the detected antibodies, the authors asked if the 
autoantibodies were specific for the kidney and for which anatomical structures. 
Using publically available transcriptome data from human organs, they selected 
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heart and pancreatic tissue and found most antibody targets not expressed and 
concluded that this approach confirmed specificity of autoantibodies. The choice 
of heart and pancreas as organs may appear questionable since other organs 
such as the intestine, the inner ear, the lung, or liver share certainly a higher 
degree of similarity from the morphological and functional point of view and 
express many proteins found in the kidney.  
Nevertheless, the authors also mapped the antigens to different kidney 
compartments based on transcriptome data from coarsely dissected human 
kidneys distinguishing seven compartments: glomerulum, outer and inner cortex, 
outer and inner medulla, pelvis, and papillary tip.  
Interestingly, the authors were able to detect non-HLA antibodies with highest 
posttransplant recognition for renal pelvis and cortex specific antigens. Among 
the top 5 antigenic targets of the pelvis, ARHGEF6, encoding a protein with 
homology to guanine nucleotide exchange factors for Rho GTPases, and 
STMN3, a small regulatory phosphoprotein integrating diverse intracellular 
signaling pathways, were used for immunohistochemistry to confirm successfully 
the compartment specific localization of both antigens in this study. Again, for a 
kidney physiologist or morphologist, the rather arbitrary dissection of the kidney 
in these seven compartments comes as a surprise since many anatomical 
structures run through several of these “compartments” and would allow for little 
meaningful discrimination between specific structures. Based on these data, the 
authors speculated that a common mechanism may exist such as ischemic-
reperfusion injury with exposure of specific antigenic targets in the pelvis that 
could trigger the autoantibody response.  
Despite some criticism on technical issues of this study, there may be several 
points to be learnt from this study. A closer look at the potential antigen targets 
detected in patients shows that for instance many autoantibodies may exist 
against proteins involved in renal collecting duct acid excretion including the 
Foxi1 transcription factor, several subunits of the vacuolar proton pump 
mediating urinary acid excretion, or the RhCG Rhesus protein. Studies in mice 
lacking Foxi1 or RhCG have shown that these proteins are critical for normal 
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renal acid excretion and that their lack causes renal tubular acidosis [8, 9]. 
Indeed, several cross-sectional studies have shown a  prevalence of about 30-40 
% of renal tubular acidosis after kidney transplantation which was not necessarily 
associated with the use of specific immunosuppressive treatments [10-12]. Thus, 
autoantibodies may contribute to this acidification defects and clinical studies will 
be necessary to test for correlation and prognostic value of such autoantibodies. 
Secondly, in parallel to allogenic transplantation, autoantibodies have a key role 
in autoimmune diseases. Although the direct pathogenetic mechanisms are not 
known for most autoantibodies, the specificity and pathogenicity of autoantibody 
responses for certain diseases have highlighted their importance for improved 
diagnosis, classification and prognosis. For instance, in systemic lupus 
erythematosus (SLE), characterized by the presence of more than hundred 
different autoantibodies, double reactive anti-dsDNA/anti-α-actinin autoantibodies 
have been shown to be nephritogenic and thus play a key role in the 
manifestation of lupus nephritis. Further, changes in titer of both antibodies are 
significantly associated with disease activity [13].  
Another autoimmune disorder affecting the kidney is primary Sjögren’s 
syndrome, a complex autoimmune disease characterized by the presence of 
autoantibodies against the ribonucleoprotein (RNP) particles SS-A/Ro and SS-
B/La, and infiltration of mononuclear cells in target organs such as salivary and 
lacrimal glands. Sjögren’s syndrome can be associated with renal manifestations 
such as distal renal tubular acidosis (dRTA) in the context of tubulointerstitial 
nephritis. The incidence of dRTA in Sjögren’s syndrome has been reported to be 
about 30% [14, 15]. To date, there is some evidence that autoantibodies against 
proteins involved in renal acid excretion such as carbonic anhydrase type II or 
subunits of the vacuolar H+-ATPase in the acid-secretory intercalated cells may 
play a pathophysiological role in Sjögren patients developing dRTA [15-17].  
  
In all these autoimmune diseases the “antibodyome” approach reported by Li and 
colleagues could provide a helpful and interesting tool to perform large-scale 
multiplex characterization of autoantibody responses directed against structurally 
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diverse autoantigens in order to investigate the specificity, relevance and 
pathogenesis of autoantibody responses.  However, the more challenging task 
will be to establish a causal role for such autoantibodies, to examine if these 
autoantibodies may be clinically useful as diagnostic and prognostic markers, or 
even as therapeutic targets. 
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